Walleye Capital LLC Raises Stock Holdings in BeiGene, Ltd. (NASDAQ:BGNE)

Walleye Capital LLC raised its stake in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) by 50.1% during the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 26,721 shares of the company's stock after acquiring an additional 8,924 shares during the quarter. Walleye Capital LLC's holdings in BeiGene were worth $5,999,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Swedbank AB bought a new position in shares of BeiGene during the 1st quarter worth $2,596,000. Raymond James & Associates boosted its position in BeiGene by 0.4% during the second quarter. Raymond James & Associates now owns 21,275 shares of the company's stock worth $3,035,000 after purchasing an additional 76 shares during the period. EFG Asset Management North America Corp. raised its position in shares of BeiGene by 21.7% in the second quarter. EFG Asset Management North America Corp. now owns 17,780 shares of the company's stock valued at $2,540,000 after purchasing an additional 3,170 shares during the period. Van ECK Associates Corp raised its position in shares of BeiGene by 8.9% in the second quarter. Van ECK Associates Corp now owns 95,577 shares of the company's stock valued at $13,636,000 after purchasing an additional 7,816 shares during the period. Finally, Fiera Capital Corp lifted its stake in shares of BeiGene by 45.9% during the 2nd quarter. Fiera Capital Corp now owns 3,736 shares of the company's stock valued at $533,000 after buying an additional 1,176 shares in the last quarter. 48.55% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, insider Titus B. Ball sold 137 shares of BeiGene stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $189.94, for a total value of $26,021.78. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, SVP Chan Henry Lee sold 1,202 shares of the company's stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $237.10, for a total transaction of $284,994.20. The disclosure for this sale can be found here. Insiders sold a total of 63,538 shares of company stock valued at $12,594,017 over the last 90 days. Insiders own 7.43% of the company's stock.

BeiGene Price Performance

Shares of BGNE stock traded up $8.84 during trading on Friday, hitting $215.00. The company had a trading volume of 258,633 shares, compared to its average volume of 285,123. BeiGene, Ltd. has a 52 week low of $126.97 and a 52 week high of $248.16. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. The stock's 50-day moving average is $212.42 and its two-hundred day moving average is $184.63.

BeiGene (NASDAQ:BGNE - Get Free Report) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $983.26 million. During the same period in the prior year, the firm posted $2.01 earnings per share. The business's revenue was up 28.2% on a year-over-year basis. Research analysts predict that BeiGene, Ltd. will post -5.38 EPS for the current fiscal year.

Analyst Ratings Changes

BGNE has been the topic of a number of analyst reports. StockNews.com cut shares of BeiGene from a "buy" rating to a "hold" rating in a report on Thursday, November 21st. Citigroup increased their price objective on BeiGene from $269.00 to $288.00 and gave the stock a "buy" rating in a report on Thursday, August 8th. TD Cowen raised their target price on BeiGene from $254.00 to $260.00 and gave the stock a "buy" rating in a research note on Wednesday, November 13th. JMP Securities began coverage on BeiGene in a research report on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 price target on the stock. Finally, JPMorgan Chase & Co. raised their price objective on shares of BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a research report on Tuesday, October 22nd. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $247.07.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.